Abstract
The causative factor of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously mutating. Interestingly, identified mutations mainly occur in the spike (S) protein which interacts with the ACE2 receptor and is cleaved via serine protease TMPRSS2. Some mutated strains are becoming dominant in various parts of the globe because of increased transmissibility as well as cell entry efficacy. Remarkably, the neutralizing activity of monoclonal antibodies, convalescent sera, and vaccines against the variants has been reported to be significantly reduced. Therefore, the efficacy of various monoclonal antibodies therapy and vaccines against these variants is becoming a great global concern. We herein summarize the current status of SARS-CoV-2 with gears shifted towards the recent and most common genetic variants in relation to transmission, neutralizing activity, and vaccine efficacy.
Article PDF
Similar content being viewed by others
References
Abdool Karim, S.S. and de Oliveira, T. 2021. New SARS-CoV-2 variants - clinical, public health, and vaccine implications. N. Engl. J. Med., 384, 1866–1868.
Ali, F., Kasry, A., and Amin, M. 2021. The new SARS-CoV-2 strain shows a stronger binding affinity to ACE2 due to N501Y mutant. Med. Drug Discov., 10, 100086.
Astuti, I. and Ysrafil. 2020. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): an overview of viral structure and host response. Diabetes Metab. Syndr., 14, 407–412.
Awadasseid, A., Wu, Y., Tanaka, Y., and Zhang, W. 2021. Current advances in the development of SARS-CoV-2 vaccines. Int. J. Biol. Sci., 17, 8–19.
Baden, L.R., El Sahly, H.M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S.A., Rouphael, N., Creech, C.B., et al. 2021. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med., 384, 403–416.
Bayati, A., Kumar, R., Francis, V., and McPherson, P.S. 2021. SARSCoV-2 infects cells after viral entry via clathrin-mediated endocytosis. J. Biol. Chem., 296, 100306.
Bestle, D., Heindl, M.R., Limburg, H., Van Lam van, T., Pilgram, O., Moulton, H., Stein, D.A., Hardes, K., Eickmann, M., Dolnik, O., et al. 2020. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci. Alliance, 3, e202000786.
Bian, L., Gao, F., Zhang, J., He, Q., Mao, Q., Xu, M., and Liang, Z. 2021. Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. Expert Rev. Vaccines, 20, 365–373.
Boehm, E., Kronig, I., Neher, R.A., Eckerle, I., Vetter, P., Kaiser, L., and Geneva Centre for Emerging Viral Diseases. 2021. Novel SARS-CoV-2 variants: the pandemics within the pandemic. Clin. Microbiol. Infect., 27, P1109–P1117.
Cagigi, A. and Loré, K. 2021. Immune responses induced by mRNA vaccination in mice, monkeys and humans. Vaccines, 9, 61.
Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. 2020. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med., 382, 1787–1799.
Cele, S., Gazy, I., Jackson, L., Hwa, S.H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., Wilkinson, E., Naidoo, Y., et al. 2021. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature, 593, 142–146.
Chakravarty, D., Nair, S.S., Hammouda, N., Ratnani, P., Gharib, Y., Wagaskar, V., Mohamed, N., Lundon, D., Dovey, Z., Kyprianou, N., et al. 2020. Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer. Commun. Biol., 3, 374.
Chan, J.F.W., Kok, K.H., Zhu, Z., Chu, H., To, K.K.W., Yuan, S., and Yuen, K.Y. 2020. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microbes Infect., 9, 221–236.
Chen, J., Wang, R., Wang, M., and Wei, G.W. 2020. Mutations strengthened SARS-CoV-2 infectivity. J. Mol. Biol., 432, 5212–5226.
Collier, D.A., De Marco, A., Ferreira, I.A.T.M., Meng, B., Datir, R.P., Walls, A.C., Kemp, S.A., Bassi, J., Pinto, D., Silacci-Fregni, C., et al. 2021. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature, 593, 136–141.
Coperchini, F., Chiovato, L., Croce, L., Magri, F., and Rotondi, M. 2020. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev., 53, 25–32.
Coutard, B., Valle, C., de Lamballerie, X., Canard, B., Seidah, N.G., and Decroly, E. 2020. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res., 176, 104742.
DeFrancesco, L. 2020. COVID-19 antibodies on trial. Nat. Biotechnol., 38, 1242–1252.
Dejnirattisai, W., Zhou, D., Supasa, P., Liu, C., Mentzer, A.J., Ginn, H.M., Zhao, Y., Duyvesteyn, H.M.E., Tuekprakhon, A., Nutalai, R., et al. 2021. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell, 184, 2939–2954.
Deng, X., Garcia-Knight, M.A., Khalid, M.M., Servellita, V., Wang, C., Morris, M.K., Sotomayor-González, A., Glasner, D.R., Reyes, K.R., Gliwa, A.S., et al. 2021. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv. doi: https://doi.org/10.1101/2021.03.07.21252647.
Eastman, R.T., Roth, J.S., Brimacombe, K.R., Simeonov, A., Shen, M., Patnaik, S., and Hall, M.D. 2020. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent. Sci., 6, 672–683.
Edara, V.V., Pinsky, B.A., Suthar, M.S., Lai, L., Davis-Gardner, M.E., Floyd, K., Flowers, M.W., Wrammert, J., Hussaini, L., Ciric, C.R., et al. 2021. Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants. N. Engl. J. Med., 385, 664–666.
Ella, R., Vadrevu, K.M., Jogdand, H., Prasad, S., Reddy, S., Sarangi, V., Ganneru, B., Sapkal, G., Yadav, P., Abraham, P., et al. 2021. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect. Dis., 21, 637–646.
Emary, K.R.W., Golubchik, T., Aley, P.K., Ariani, C.V., Angus, B., Bibi, S., Blane, B., Bonsall, D., Cicconi, P., Charlton, S., et al. 2021. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARSCoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, 397, 1351–1362.
Faria, N.R., Mellan, T.A., Whittaker, C., Claro, I.M., Candido, D.d.S., Mishra, S., Crispim, M.A.E., Sales, F.C.S., Hawryluk, I., McCrone, J.T., et al. 2021. Genomics and epidemiology of the P.1 SARSCoV-2 lineage in Manaus, Brazil. Science, 372, 815–821.
Fathi, N. and Rezaei, N. 2020. Lymphopenia in COVID-19: Therapeutic opportunities. Cell Biol. Int., 44, 1792–1797.
Fehr, A.R. and Perlman, S. 2015. Coronaviruses: an overview of their replication and pathogenesis. In Maier, H., Bickerton, E., and Britton, P. (eds.), Coronaviruses. Methods in Molecular Biology, vol. 1282, Humana Press, New York, USA.
Focosi, D., Tuccori, M., Baj, A., and Maggi, F. 2021. SARS-CoV-2 variants: a synopsis of in vitro efficacy data of convalescent plasma, currently marketed vaccines, and monoclonal antibodies. Viruses, 13, 1211.
Gao, Y.M., Xu, G., Wang, B., and Liu, B.C. 2021. Cytokine storm syndrome in coronavirus disease 2019: A narrative review. J. Intern. Med. 289, 147–161.
Gao, S. and Zhang, L. 2020. ACE2 partially dictates the host range and tropism of SARS-CoV-2. Comput. Struct. Biotechnol. J., 18, 4040–4047.
Garcia-Beltran, W.F., Lam, E.C., Astudillo, M.G., Yang, D., Miller, T.E., Feldman, J., Hauser, B.M., Caradonna, T.M., Clayton, K.L., Nitido, A.D., et al. 2021. COVID-19-neutralizing antibodies predict disease severity and survival. Cell, 184, 476–488.
Gautret, P., Lagier, J.C., Parola, P., Hoang, V.T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V.E., et al. 2020. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents, 56, 105949.
Gheblawi, M., Wang, K., Viveiros, A., Nguyen, Q., Zhong, J.-C., Turner, A.J., Raizada, M.K., Grant, M.B., and Oudit, G.Y. 2020. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system. Circ. Res., 126, 1456–1474.
Glowacka, I., Bertram, S., Herzog, P., Pfefferle, S., Steffen, I., Muench, M.O., Simmons, G., Hofmann, H., Kuri, T., Weber, F., et al. 2010. Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63. J. Virol., 84, 1198–1205.
Gottlieb, R.L., Nirula, A., Chen, P., Boscia, J., Heller, B., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. 2021. Effect of bamlanivimab as monotherapy or in combination with Etesevimab on viral load in patients with mild to moderate COVID-19. JAMA, 325, 632–644.
Gralinski, L.E. and Menachery, V.D. 2020. Return of the coronavirus: 2019-nCoV. Viruses, 12, 135.
Greaney, A.J., Loes, A.N., Crawford, K.H.D., Starr, T.N., Malone, K.D., Chu, H.Y., and Bloom, J.D. 2021. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe, 29, 463–476.
Haji Abdolvahab, M., Moradi-kalbolandi, S., Zarei, M., Bose, D., Majidzadeh-A, K., and Farahmand, L. 2021. Potential role of interferons in treating COVID-19 patients. Int. Immunopharmacol. 90, 107171.
Hamed, S.M., Elkhatib, W.F., Khairalla, A.S., and Noreddin, A.M. 2021. Global dynamics of SARS-CoV-2 clades and their relation to COVID-19 epidemiology. Sci. Rep., 11, 8435.
Han, Q., Lin, Q., Jin, S., and You, L. 2020. Coronavirus 2019-nCoV: a brief perspective from the front line. J. Infect., 80, 373–377.
Hansen, J., Baum, A., Pascal, K.E., Russo, V., Giordano, S., Wloga, E., Fulton, B.O., Yan, Y., Koon, K., Patel, K., et al. 2020. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science, 369, 1010–1014.
Harvey, W.T., Carabelli, A.M., Jackson, B., Gupta, R.K., Thomson, E.C., Harrison, E.M., Ludden, C., Reeve, R., Rambaut, A., Peacock, S.J., et al. 2021. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol., 19, 409–424.
Heath, P.T., Galiza, E.P., Baxter, D.N., Boffito, M., Browne, D., Burns, F., Chadwick, D.R., Clark, R., Cosgrove, C., Galloway, J., et al. 2021. Efficacy of the NVX-CoV2373 covid-19 vaccine against the B.1.1.7 variant. N. Engl. J. Med. doi: https://doi.org/10.1056/NEJMoa2107659.
Hitchings, M.D.T., Ranzani, O.T., Scaramuzzini Torres, M.S., de Oliveira, S.B., Almiron, M., Said, R., Borg, R., Schulz, W.L., de Oliveira, R.D., da Silva, P.V., et al. 2021. Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: a test-negative case-control study. medRxiv. doi: https://doi.org/10.1101/2021.04.07.21255081.
Hoffmann, M., Arora, P., Groß, R., Seidel, A., Hörnich, B.F., Hahn, A.S., Krüger, N., Graichen, L., Hofmann-Winkler, H., Kempf, A., et al. 2021a. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell, 184, 2384–2393.
Hoffmann, M., Hofmann-Winkler, H., Krüger, N., Kempf, A., Nehlmeier, I., Graichen, L., Arora, P., Sidarovich, A., Moldenhauer, A.S., Winkler, M.S., et al. 2021b. SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. Cell Rep., 36, 109415.
Huang, B., Dai, L., Wang, H., Hu, Z., Yang, X., Tan, W., and Gao, G.F. 2021. Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines. bioRxiv, doi: https://doi.org/10.1101/2021.02.01.429069.
Hui, K.P.Y., Cheung, M.C., Perera, R.A.P.M., Ng, K.C., Bui, C.H.T., Ho, J.C.W., Ng, M.M.T., Kuok, D.I.T., Shih, K.C., Tsao, S.W., et al. 2020. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. Lancet Respir. Med., 8, 687–695.
Ivanov, K.A., Thiel, V., Dobbe, J.C., van der Meer, Y., Snijder, E.J., and Ziebuhr, J. 2004. Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase. J. Virol., 78, 5619–5632.
Jackson, L.A., Anderson, E.J., Rouphael, N.G., Roberts, P.C., Makhene, M., Coler, R.N., McCullough, M.P., Chappell, J.D., Denison, M.R., Stevens, L.J., et al. 2020. An mRNA vaccine against SARS-CoV-2 - preliminary report. N. Engl. J. Med., 383, 1920–1931.
Jeyanathan, M., Afkhami, S., Smaill, F., Miller, M.S., Lichty, B.D., and Xing, Z. 2020. Immunological considerations for COVID-19 vaccine strategies. Nat. Rev. Immunol., 20, 615–632.
Jiang, S., Zhang, X., Yang, Y., Hotez, P.J., and Du, L. 2020. Neutralizing antibodies for the treatment of COVID-19. Nat. Biomed. Eng., 4, 1134–1139.
Juraszek, J., Rutten, L., Blokland, S., Bouchier, P., Voorzaat, R., Ritschel, T., Bakkers, M.J.G., Renault, L.L.R., and Langedijk, J.P.M. 2021. Stabilizing the closed SARS-CoV-2 spike trimer. Nat. Commun., 12, 244.
Khalili, J.S., Zhu, H., Mak, N.S.A., Yan, Y., and Zhu, Y. 2020. Novel coronavirus treatment with ribavirin: groundwork for an evaluation concerning COVID-19. J. Med. Virol., 92, 740–746.
Kiani, P., Scholey, A., Dahl, T.A., McMann, L., Iversen, J.M., and Verster, J.C. 2021. In vitro assessment of the antiviral activity of ketotifen, indomethacin and naproxen, alone and in combination, against SARS-CoV-2. Viruses, 13, 558.
Kim, Y.J., Jang, U.S., Soh, S.M., Lee, J.Y., and Lee, H.R. 2021. The impact on infectivity and neutralization efficiency of SARS-CoV-2 lineage B.1.351 Pseudovirus. Viruses, 13, 633.
Kirchdoerfer, R.N. and Ward, A.B. 2019. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat. Commun., 10, 2342.
Koyama, T., Platt, D., and Parida, L. 2020. Variant analysis of SARSCoV- 2 genomes. Bull. World Health Organ., 98, 495–504.
Krammer, F. 2020. SARS-CoV-2 vaccines in development. Nature, 586, 516–527.
Kyriakidis, N.C., Löpez-Cortés, A., González, E.V., Grimaldos, A.B., and Prado, E.O. 2021. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines, 6, 28.
La Rosa, G., Mancini, P., Bonanno Ferraro, G., Veneri, C., Iaconelli, M., Lucentini, L., Bonadonna, L., Brusaferro, S., Brandtner, D., Fasanella, A., et al. 2021. Rapid screening for SARS-CoV-2 variants of concern in clinical and environmental samples using nested RT-PCR assays targeting key mutations of the spike protein. Water Res., 197, 117104.
Li, X., Geng, M., Peng, Y., Meng, L., and Lu, S. 2020. Molecular immune pathogenesis and diagnosis of COVID-19. J. Pharm. Anal., 10, 102–108.
Lippi, G., Sanchis-Gomar, F., and Henry, B.M. 2020. COVID-19: unravelling the clinical progression of nature's virtually perfect biological weapon. Ann. Transl. Med., 8, 693.
Liu, C., Ginn, H.M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., Zhou, D., Mentzer, A.J., Zhao, Y., et al. 2021a. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell, 184, 4220–4236.
Liu, J., Liu, Y., Xia, H., Zou, J., Weaver, S.C., Swanson, K.A., Cai, H., Cutler, M., Cooper, D., Muik, A., et al. 2021b. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature, 596, 273–275.
Liu, H., Wei, P., Zhang, Q., Chen, Z., Aviszus, K., Downing, W., Peterson, S., Reynoso, L., Downey, G.P., Frankel, S.K., et al. 2021c. 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro. mAbs, 13, 1919285.
Lloyd, E.C., Gandhi, T.N., and Petty, L.A. 2021. Monoclonal antibodies for COVID-19. JAMA, 325, 1015.
Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. 2021. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N. Engl. J. Med., 385, 585–594.
Luan, B., Wang, H., and Huynh, T. 2021. Enhanced binding of the N501Y-mutated SARS-CoV-2 spike protein to the human ACE2 receptor: insights from molecular dynamics simulations. FEBS Lett., 595, 1454–1461.
Macia, E., Ehrlich, M., Massol, R., Boucrot, E., Brunner, C., and Kirchhausen, T. 2006. Dynasore, a cell-permeable inhibitor of dynamin. Dev. Cell, 10, 839–850.
Madhi, S.A., Baillie, V., Cutland, C.L., Voysey, M., Koen, A.L., Fairlie, L., Padayachee, S.D., Dheda, K., Barnabas, S.L., Bhorat, Q.E., et al. 2021. Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa. N. Engl. J. Med., 384, 1885–1898.
Mahase, E. 2020. Covid-19: FDA authorises neutralising antibody bamlanivimab for non-admitted patients. BMJ, 371, m4362.
Mahase, E. 2021. How the Oxford-AstraZeneca covid-19 vaccine was made. BMJ, 372, n86.
Market, M., Angka, L., Martel, A.B., Bastin, D., Olanubi, O., Tennakoon, G., Boucher, D.M., Ng, J., Ardolino, M., and Auer, R.C. 2020. Flattening the COVID-19 curve with natural killer cell based immunotherapies. Front. Immunol., 11, 1512.
Masters, P.S. 2006. The molecular biology of coronaviruses. Adv. Virus Res., 66, 193–292.
McCallum, M., Bassi, J., Marco, A.D., Chen, A., Walls, A.C., Iulio, J.D., Tortorici, M.A., Navarro, M.J., Silacci-Fregni, C., Saliba, C., et al. 2021a. SARS-CoV-2 immune evasion by variant B.1.427/B.1.429. Science, 373, 648–654.
McCallum, M., Marco, A.D., Lempp, F., Tortorici, M.A., Pinto, D., Walls, A.C., Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. 2021b. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell, 184, 2332–2347.
Mercatelli, D. and Giorgi, F.M. 2020. Geographic and genomic distribution of SARS-CoV-2 mutations. Front. Microbiol., 11, 1800.
Min, L. and Sun, Q. 2021. Antibodies and vaccines target RBD of SARS-CoV-2. Front. Mol. Biosci. 8, 671633.
Mlcochova, P., Kemp, S.A., Shanker Dhar, M., Papa, G., Meng, B., Mishra, S., Whittaker, C., Mellan, T., Ferreira, I., Datir, R., et al. 2021. SARS-CoV-2 B.1.617.2 Delta variant emergence and vaccine breakthrough. bioRxiv. doi: https://doi.org/10.1101/2021.05.08.443253.
Motozono, C., Toyoda, M., Zahradnik, J., Saito, A., Nasser, H., Tan, T.S., Ngare, I., Kimura, I., Uriu, K., Kosugi, Y., et al. 2021. SARSCoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host Microbe, 29, 1124–1136.
Muik, A., Wallisch, A.K., Sänger, B., Swanson, K.A., Mühl, J., Chen, W., Cai, H., Maurus, D., Sarkar, R., Türeci, Ö., et al. 2021. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT-162b2 vaccine-elicited human sera. Science, 371, 1152–1153.
Nikolich-Zugich, J., Knox, K.S., Rios, C.T., Natt, B., Bhattacharya, D., and Fain, M.J. 2020. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. GeroScience, 42, 505–514.
Nkengasong, J. 2020. China's response to a novel coronavirus stands in stark contrast to the 2002 SARS outbreak response. Nat. Med., 26, 310–311.
Ou, J., Zhou, Z., Dai, R., Zhang, J., Zhao, S., Wu, X., Lan, W., Ren, Y., Cui, L., Lan, Q., et al. 2021. V367F mutation in SARS-CoV-2 spike RBD emerging during the early transmission phase enhances viral infectivity through increased human ACE2 receptor binding affinity. J. Virol., 95, e0061721.
Ozono, S., Zhang, Y., Ode, H., Sano, K., Tan, T.S., Imai, K., Miyoshi, K., Kishigami, S., Ueno, T., Iwatani, Y., et al. 2021. SARS-CoV-2 D614G S mutation increases entry efficiency with enhanced ACE2-binding affinity. Nat. Commun., 12, 848.
Parry, H.M., Tut, G., Faustini, S., Stephens, C., Saunders, P., Bentley, C., Hilyard, K., Brown, K., Amirthalingam, G., Charlton, S., et al. 2021. BNT162b2 vaccination in people over 80 years of age induces strong humoral immune responses with cross neutralisation of P.1 Brazilian variant. SSRN. doi: https://doi.org/10.2139/ssrn.3816840.
Picchianti Diamanti, A., Rosado, M.M., Pioli, C., Sesti, G., and Laganà, B. 2020. Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern: the fragile balance between infections and autoimmunity. Int. J. Mol. Sci., 21, 3330.
Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M.M., Bishop, E., et al. 2021. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat. Med., 27, 917–924.
Poduri, R., Joshi, G., and Jagadeesh, G. 2020. Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. Cell. Signal., 74, 109721.
Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Pérez Marc, G., Moreira, E.D., Zerbini, C., et al. 2020. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N. Engl. J. Med., 383, 2603–2615.
Poland, G.A., Ovsyannikova, I.G., Crooke, S.N., and Kennedy, R.B. 2020. SARS-CoV-2 vaccine development: current status. Mayo Clin. Proc., 95, 2172–2188.
Post, N., Eddy, D., Huntley, C., van Schalkwyk, M.C.I., Shrotri, M., Leeman, D., Rigby, S., Williams, S.V., Bermingham, W.H., Kellam, P., et al. 2020. Antibody response to SARS-CoV-2 infection in humans: A systematic review. PLoS ONE, 15, e0244126.
Ragab, D., Salah Eldin, H., Taeimah, M., Khattab, R., and Salem, R. 2020. The COVID-19 cytokine storm; What we know so far. Front. Immunol., 11, 1446.
Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., de Groot, A.M., Stoop, J., Tete, S., Van Damme, W., Leroux-Roels, I., et al. 2021. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N. Engl. J. Med., 384, 1824–1835.
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L.M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. 2020. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. medRxiv. doi: https://doi.org/10.1101/2020.12.09.20245175.
Sapkal, G.N., Yadav, P.D., Ella, R., Deshpande, G.R., Sahay, R.R., Gupta, N., Mohan, V.K., Abraham, P., Panda, S., and Bhargava, B. 2021. Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum. bioRxiv. doi: https://doi.org/10.1101/2021.01.26.426986.
Sengupta, A., Hassan, S.S., and Choudhury, P.P. 2021. Clade GR and clade GH isolates of SARS-CoV-2 in Asia show highest amount of SNPs. Infect. Genet. Evol., 89, 104724.
Sevajol, M., Subissi, L., Decroly, E., Canard, B., and Imbert, I. 2014. Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus. Virus Res., 194, 90–99.
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., and Li, F. 2020. Structural basis of receptor recognition by SARS-CoV-2. Nature, 581, 221–224.
Shen, X., Tang, H., McDanal, C., Wagh, K., Fischer, W., Theiler, J., Yoon, H., Li, D., Haynes, B.F., Sanders, K.O., et al. 2021. SARSCoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe, 29, 529–539.
Singh, J., Samal, J., Kumar, V., Sharma, J., Agrawal, U., Ehtesham, N.Z., Sundar, D., Rahman, S.A., Hira, S., and Hasnain, S.E. 2021. Structure-function analyses of new SARS-CoV-2 variants B.1.1.7, B.1.351 and B.1.1.28.1: clinical, diagnostic, therapeutic and public health implications. Viruses, 13, 439.
Song, H.D., Tu, C.C., Zhang, G.W., Wang, S.Y., Zheng, K., Lei, L.C., Chen, Q.X., Gao, Y.W., Zhou, H.Q., Xiang, H., et al. 2005. Crosshost evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc. Natl. Acad. Sci. USA, 102, 2430–2435.
Stephenson, K.E., Le Gars, M., Sadoff, J., de Groot, A.M., Heerwegh, D., Truyers, C., Atyeo, C., Loos, C., Chandrashekar, A., McMahan, K., et al. 2021. Immunogenicity of the Ad26.COV2.S vaccine for COVID-19. JAMA, 325, 1535–1544.
Sternberg, A. and Naujokat, C. 2020. Structural features of coronavirus SARS-CoV-2 spike protein: targets for vaccination. Life Sci., 257, 118056.
Supasa, P., Zhou, D., Dejnirattisai, W., Liu, C., Mentzer, A.J., Ginn, H.M., Zhao, Y., Duyvesteyn, H.M.E., Nutalai, R., Tuekprakhon, A., et al. 2021. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell, 184, 2201–2211.
Tada, T., Zhou, H., Dcosta, B.M., Samanovic, M.I., Mulligan, M.J., and Landau, N.R. 2021. The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies. bioRxiv. doi: https://doi.org/10.1101/2021.05.14.444076.
Tay, M.Z., Poh, C.M., Rénia, L., MacAry, P.A., and Ng, L.F.P. 2020. The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol., 20, 363–374.
Tian, J.H., Patel, N., Haupt, R., Zhou, H., Weston, S., Hammond, H., Logue, J., Portnoff, A.D., Norton, J., Guebre-Xabier, M., et al. 2021. SARS-CoV-2 S glycoprotein vaccine candidate NVXCoV2373 immunogenicity in baboons and protection in mice. Nat. Commun., 12, 372.
Ura, T., Yamashita, A., Mizuki, N., Okuda, K., and Shimada, M. 2021. New vaccine production platforms used in developing SARSCoV-2 vaccine candidates. Vaccine, 39, 197–201.
US FDA, US Food & Drug Administration. 2020. Coronavirus (COVID-19) update: FDA authorizes monoclonal antibodies for treatment of COVID-19. (accessed 13 May 2021). https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatmentcovid-19
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J.J.V., Pfeffer, M.A., and Solomon, S.D. 2020. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N. Engl. J. Med., 382, 1653–1659.
Verbeke, R., Lentacker, I., De Smedt, S.C., and Dewitte, H. 2021. The dawn of mRNA vaccines: the COVID-19 case. J. Control. Release, 333, 511–520.
von Kleist, L., Stahlschmidt, W., Bulut, H., Gromova, K., Puchkov, D., Robertson, M.J., MacGregor, K.A., Tomilin, N., Pechstein, A., Chau, N., et al. 2011. Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition. Cell, 146, 471–484.
Walls, A.C., Park, Y.J., Tortorici, M.A., Wall, A., McGuire, A.T., and Veesler, D. 2020. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell, 181, 281–292.
Wang, P., Casner, R.G., Nair, M.S., Wang, M., Yu, J., Cerutti, G., Liu, L., Kwong, P.D., Huang, Y., Shapiro, L., et al. 2021a. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe, 29, 747–751.
Wang, W.B., Liang, Y., Jin, Y.Q., Zhang, J., Su, J.G., and Li, Q.M. 2021b. E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: binding free energy calculation studies. bioRxiv. doi: https://doi.org/10.1101/2021.02.17.431566.
Wang, P., Nair, M.S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P.D., et al. 2021c. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature, 593, 130–135.
Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C.O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J.A., et al. 2021d. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature, 592, 616–622.
Wang, Q., Wu, J., Wang, H., Gao, Y., Liu, Q., Mu, A., Ji, W., Yan, L., Zhu, Y., Zhu, C., et al. 2020. Structural basis for RNA replication by the SARS-CoV-2 polymerase. Cell, 182, 417–428.
Weinreich, D.M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., Musser, B.J., Soo, Y., Rofail, D., Im, J., et al. 2021. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N. Engl. J. Med., 384, 238–251.
Wibmer, C.K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B.E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. 2021. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat. Med., 27, 622–625.
Widera, M., Wilhelm, A., Hoehl, S., Pallas, C., Kohmer, N., Wolf, T., Rabenau, H.F., Corman, V., Drosten, C., Vehreschild, M.J.G.T., et al. 2021. Bamlanivimab does not neutralize two SARS-CoV-2 variants carrying E484K in vitro. medRxiv. doi: https://doi.org/10.1101/2021.02.24.21252372.
Wong, L.H., Edgar, J.R., Martello, A., Ferguson, B.J., and Eden, E.R. 2021. Exploiting connections for viral replication. Front. Cell Dev. Biol., 9, 640456.
Xie, X., Liu, Y., Liu, J., Zhang, X., Zou, J., Fontes-Garfias, C.R., Xia, H., Swanson, K.A., Cutler, M., Cooper, D., et al. 2021. Neutralization of SARS-CoV-2 S 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat. Med., 27, 620–621.
Yadav, P.D., Mohandas, S., Shete, A.M., Nyayanit, D.A., Gupta, N., Patil, D.Y., Sapkal, G.N., Potdar, V., Kadam, M., Kumar, A., et al. 2021. SARS CoV-2 variant B.1.617.1 is highly pathogenic in hamsters than B.1 variant. bioRxiv. doi: https://doi.org/10.1101/2021.05.05.442760.
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. 2020. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med., 8, 475–481.
Yin, W., Mao, C., Luan, X., Shen, D.D., Shen, Q., Su, H., Wang, X., Zhou, F., Zhao, W., Gao, M., et al. 2020. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARSCoV-2 by remdesivir. Science, 368, 1499–1504.
Young, B.E., Ong, S.W.X., Kalimuddin, S., Low, J.G., Tan, S.Y., Loh, J., Ng, O.T., Marimuthu, K., Ang, L.W., Mak, T.M., et al. 2020. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA, 323, 1488–1494
Zhou, D., Dejnirattisai, W., Supasa, P., Liu, C., Mentzer, A.J., Ginn, H.M., Zhao, Y., Duyvesteyn, H.M.E., Tuekprakhon, A., Nutalai, R., et al. 2021. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell, 184, 2348–2361.
Zhou, R., To, K.K.W., Wong, Y.C., Liu, L., Zhou, B., Li, X., Huang, H., Mo, Y., Luk, T.Y., Lau, T.T.K., et al. 2020. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. Immunity, 53, 864–877.
Acknowledgements
This work was supported by the National Research Foundation of Korea (NRF), grant number 2020M3A9I2081695, 2018M3A9H4089656, and 2021R1A4A1028969 (to H.R.L). Due to immune space limitations, we sincerely apologize for not being able to cite all papers related to this topic.
Author information
Authors and Affiliations
Corresponding author
Additional information
Conflict of Interest
The authors have no conflict of interest to report.
Rights and permissions
About this article
Cite this article
Soh, S.M., Kim, Y., Kim, C. et al. The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance. J Microbiol. 59, 807–818 (2021). https://doi.org/10.1007/s12275-021-1348-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12275-021-1348-5